Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M. Younossi, Victor Ankoma‐Sey, Andreas Geier et al.|The Lancet|2019Cited by 1.2k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis WorseningVlad Ratziu, Velimir A. Luketic, Juan F. Gallegos‐Orozco et al.|Gastroenterology|2016Cited by 1k
Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given lateAdriano Pellicelli, M. Angélico, Marzia Montalbano et al.|Digestive and Liver Disease|2014Cited by 103